Kurzyńska, A.; Pach, D.; Skalniak, A.E.; Stefańska, A.; Opalińska, M.; Przybylik-Mazurek, E.; Hubalewska-Dydejczyk, A.
Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors—Potential Clinical Relevance. J. Clin. Med. 2022, 11, 5536.
https://doi.org/10.3390/jcm11195536
AMA Style
Kurzyńska A, Pach D, Skalniak AE, Stefańska A, Opalińska M, Przybylik-Mazurek E, Hubalewska-Dydejczyk A.
Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors—Potential Clinical Relevance. Journal of Clinical Medicine. 2022; 11(19):5536.
https://doi.org/10.3390/jcm11195536
Chicago/Turabian Style
Kurzyńska, Anna, Dorota Pach, Anna Elżbieta Skalniak, Agnieszka Stefańska, Marta Opalińska, Elwira Przybylik-Mazurek, and Alicja Hubalewska-Dydejczyk.
2022. "Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors—Potential Clinical Relevance" Journal of Clinical Medicine 11, no. 19: 5536.
https://doi.org/10.3390/jcm11195536
APA Style
Kurzyńska, A., Pach, D., Skalniak, A. E., Stefańska, A., Opalińska, M., Przybylik-Mazurek, E., & Hubalewska-Dydejczyk, A.
(2022). Prevalence of Selected Single-Nucleotide Variants in Patients with Neuroendocrine Tumors—Potential Clinical Relevance. Journal of Clinical Medicine, 11(19), 5536.
https://doi.org/10.3390/jcm11195536